Opinion/decision on a Paediatric investigation plan (PIP): Evenity, romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0375/2024

Opinion/decision on a Paediatric investigation plan (PIP): Noxafil, posaconazole, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0376/2024

Opinion/decision on a Paediatric investigation plan (PIP): Stelara, ustekinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0370/2024

Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0382/2024

EMEA-002905-PIP01-20-M01

EMEA-003133-PIP01-21-M01

EMEA-003174-PIP01-21-M02

EMEA-003426-PIP01-23-M02

Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 2, Status: Authorised